CO2023017754A2 - Polipéptidos modificados - Google Patents

Polipéptidos modificados

Info

Publication number
CO2023017754A2
CO2023017754A2 CONC2023/0017754A CO2023017754A CO2023017754A2 CO 2023017754 A2 CO2023017754 A2 CO 2023017754A2 CO 2023017754 A CO2023017754 A CO 2023017754A CO 2023017754 A2 CO2023017754 A2 CO 2023017754A2
Authority
CO
Colombia
Prior art keywords
polypeptides
modified polypeptides
variants
polypeptide
modified
Prior art date
Application number
CONC2023/0017754A
Other languages
English (en)
Inventor
Davide Corti
Istvan Bartha
Nadine Czudnochowski
Michael Alexander Schmid
Gyorgy Snell
Amalio Telenti
Original Assignee
Humabs Biomed Sa
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Vir Biotechnology Inc filed Critical Humabs Biomed Sa
Publication of CO2023017754A2 publication Critical patent/CO2023017754A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se proporcionan polipéptidos modificados (por ejemplo, polipéptidos de Fc, fragmentos de polipéptidos de Fc, proteínas de fusión de Fc, anticuerpos y similares) que comprenden una variante de un polipéptido de Fc de IgG (o una porción o fragmento del mismo), variantes (y los polipéptidos que comprenden estas variantes) las cuales tienen una o más características mejoradas sobre polipéptidos de Fc conocidos.
CONC2023/0017754A 2021-05-24 2023-12-19 Polipéptidos modificados CO2023017754A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163192549P 2021-05-24 2021-05-24
US202163265032P 2021-12-06 2021-12-06
US202263266453P 2022-01-05 2022-01-05
PCT/US2022/030556 WO2022251119A2 (en) 2021-05-24 2022-05-23 Engineered polypeptides

Publications (1)

Publication Number Publication Date
CO2023017754A2 true CO2023017754A2 (es) 2024-05-10

Family

ID=82156443

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017754A CO2023017754A2 (es) 2021-05-24 2023-12-19 Polipéptidos modificados

Country Status (10)

Country Link
EP (1) EP4347642A2 (es)
JP (1) JP2024521131A (es)
KR (1) KR20240035758A (es)
AU (1) AU2022280767A1 (es)
BR (1) BR112023024494A2 (es)
CA (1) CA3218489A1 (es)
CO (1) CO2023017754A2 (es)
IL (1) IL308509A (es)
TW (1) TW202306978A (es)
WO (1) WO2022251119A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2024026411A1 (en) 2022-07-27 2024-02-01 Humabs Biomed Sa Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
DE602004030700D1 (de) 2003-09-24 2011-02-03 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin-like growth factor
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
EP2282770B1 (en) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
SG11202002261VA (en) 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
WO2020251834A1 (en) * 2019-06-11 2020-12-17 The Rockefeller University Antibodies and methods for treatment of viral infections

Also Published As

Publication number Publication date
AU2022280767A1 (en) 2024-01-18
WO2022251119A2 (en) 2022-12-01
TW202306978A (zh) 2023-02-16
BR112023024494A2 (pt) 2024-02-06
JP2024521131A (ja) 2024-05-28
WO2022251119A9 (en) 2023-10-05
WO2022251119A3 (en) 2023-01-12
IL308509A (en) 2024-01-01
KR20240035758A (ko) 2024-03-18
EP4347642A2 (en) 2024-04-10
CA3218489A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2023017754A2 (es) Polipéptidos modificados
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
PE20220256A1 (es) Sistemas de casx artificiales
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
CL2021000987A1 (es) Proteínas de fusión del péptido similar al glucagón 1 (glp1)-factor de diferenciación del crecimiento 15 (gdf15) y usos de las mismas.
MX2020004013A (es) Composiciones y metodos para la degradacion selectiva de proteinas.
MX2019009817A (es) Anticuerpos anti-tau y metodos de uso de los mismos.
NO20054836L (no) Nogo-reseptorbindingsprotein
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
MX2021003580A (es) Nuevas inmunocitocinas para el tratamiento contra el cancer.
CO2019002482A2 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
CY1111286T1 (el) Ανοσοποιηση διαμεσολαβουμενη απο βακτηριοφαγα
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
PE20230381A1 (es) Proteina de union a rgma
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA202091509A1 (ru) Aav-опосредованная доставка терапевтических антител во внутреннее ухо
MX2020003748A (es) Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
EA202190653A1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
CO2022010337A2 (es) Anticuerpos monoclonales anti-sirpα y usos de los mismos
CL2020003391A1 (es) Proteína de unión al antígeno anti-steap1
BR112023017749A2 (pt) Composições incluindo adjuvantes sbi e métodos de uso das mesmas